Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.
Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.
复制标题
DOI：
10.1136/bjophthalmol-2019-314446
复制
发表时间：
2020-05
期刊：
影响因子：
--
通讯作者：
Keane PA
中科院分区：
文献类型：
--
作者：
Fasler K;Fu DJ;Moraes G;Wagner S;Gokhale E;Kortuem K;Chopra R;Faes L;Preston G;Pontikos N;Patel PJ;Tufail A;Lee AY;Balaskas K;Keane PA
新生血管性年龄相关性黄斑变性（nAMD）通常是双侧的，以前关于“对侧眼”的报道仅在第一只眼治疗一段时间后进行序贯治疗。本研究的目的是分析nAMD对侧眼受累的基线特征和视力（VA）结局，特别是区分序贯和非序贯（由于第一只眼的黄斑瘢痕形成）抗血管内皮生长因子治疗和对侧眼受累的时间表。对Moorfields AMD数据库进行的回顾性电子病历数据库研究，该数据库包含6265例患者/120，286个单一条目，数据提取时间为2008年10月21日至2018年8月9日。用于分析的数据集包括1180只连续眼、807只非连续眼和3410只单侧眼。平均VA基线时序贯治疗的对侧眼（早期治疗糖尿病视网膜病变研究字母±SD）显著较高（63±13），2年内VA增加较低（0.37±14），视力良好眼比例（≥70个字母）高于（46%）相应的第一只眼睛（基线VA 54±16，第2年VA增加5.6±15，VA良好的眼睛百分比39%）。非连续的对侧眼显示出与第一眼相似的基线特征和视力结局。2年时对侧眼受累率为32%，对侧眼受累的中位时间间隔为71（IQR 27-147）周。本报告显示，治疗2年后，序贯治疗的nAMD对侧眼的基线和最终VA优于非序贯治疗的对侧眼。2年后，序贯治疗的患眼视力良好的比例也更高。根据年龄，32%的新生血管性AMD患者在2年内发生对侧眼受累。对侧眼睛通常能保持更好的视力，除非第一只眼睛的晚期疾病未经治疗。
Neovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on ‘fellow eyes” have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) anti-vascular endothelial growth factor treatment and timelines for fellow eye involvement. Retrospective, electronic medical record database study of the Moorfields AMD database of 6265 patients /120,286 single entries with data extracted between October 21, 2008 and August 9, 2018. The dataset for analysis consisted of 1180 sequential, 807 nonsequential, and 3410 unilateral eyes. Mean VA (Early Treatment Diabetic Retinopathy Study letters±SD) of sequentially treated fellow eyes at baseline was significantly higher (63±13), VA gain over two years lower (0.37±14), and proportion of eyes with good VA (≥70 letters) higher (46%) than the respective first eyes (baseline VA 54±16, VA gain at two years 5.6±15, percentage of eyes with good VA 39%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at two years, and median time interval to fellow eye involvement was 71 (IQR 27–147) weeks. This report shows sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years. Depending on age, fellow eye involvement occurs in 32% of patients with neovascular AMD by two years. Fellow eyes generally maintain better vision, except in cases where late-stage disease in the first eye was untreated.
登录
查看更多内容
影响因子：
13.7
作者：
Tufail, Adnan;Xing, Wen;Bunce, Catey
通讯作者：
Bunce, Catey
影响因子：
13.7
作者：
Zarranz-Ventura, Javier;Liew, Gerald;Tufail, Adnan
通讯作者：
Tufail, Adnan
影响因子：
3.5
作者：
Paulus, Yannis M.;Jefferys, Joan L.;Scott, Adrienne W.
通讯作者：
Scott, Adrienne W.
DOI：
10.1097/iae.0000000000000717
发表时间：
2016-02-01
影响因子：
3.3
作者：
Brown, Melissa M.;Brown, Gary C.;Colman, Shoshana
通讯作者：
Colman, Shoshana
影响因子：
158.5
作者：
Rosenfeld, Philip J.;Brown, David M.;Kim, Robert Y.
通讯作者：
Kim, Robert Y.